TSMC's Strong Outlook Boosts Tech Stocks, Futures Up Modestly
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Stock futures are experiencing modest gains in early trading as optimism around a strong outlook from Taiwan Semiconductor Manufacturing bolsters technology sentiment and lifts semiconductor and AI-related shares. This suggests investor risk appetite is returning after recent weaker sessions. Analysts note that TSMC's robust quarterly results and plans for expanded U.S. manufacturing have injected fresh confidence into the chip sector and could support broader tech leadership even as markets await further corporate earnings.Still, broader sentiment remains mixed and cautious after a two-day losing streak for major U.S. indexes, driven by profit-taking in technology shares and concerns around banking sector pressures, including regulatory risks and proposals on credit card rate caps that have weighed on financial stocks.Currency and bond markets have also shifted in response to these cross-currents, contributing to the broader risk-on yet cautious tone.In pre-market trading, S&P 500 futures rose 0.49%, Nasdaq futures rose 1.07% and Dow futures slipped 0.07%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Penumbraup 13% after entering into a definitive agreement under which Boston Scientificwill acquire the company in a cash and stock transaction that values Penumbra at $374 per shareSpotifyup 1% after announcing that it is raising prices for premium subscriptionsUP AFTER EARNINGS -TSMCup 5%Insteelup 5%BlackRockup 2%DOWN AFTER EARNINGS -Morgan Stanleydown 1%Goldman Sachsdown 1%LOWER -Boston Scientificdown 4% after announcing its agreement to acquire PenumbraInstacartdown 5% after Uberand Krogerannounced the launch of nearly 2,700 stores on the Uber Eats, Uber, and Postmates apps
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 57.640
Low
94.00
Averages
108.14
High
132.00
Current: 57.640
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Shares Hit 52-Week Low Amid Demand Slowdown
- Demand Slowdown Impact: Boston Scientific (BSX) shares fell approximately 10% in the morning on Wednesday, reaching a 52-week low primarily due to a persistent slowdown in demand for its WATCHMAN cardiac implant, indicating a weakening market for this product.
- Lowered Growth Outlook: During its Q1 2026 earnings release, the company revised its full-year organic net sales growth forecast down to 6.5%-8.0%, largely attributed to headwinds in WATCHMAN volumes and its electrophysiology business in the U.S.
- Market Share Challenges: CEO Michael Mahoney confirmed at an investor conference that standalone WATCHMAN growth remains a challenge, despite the company holding a 90%-91% market share in that area, indicating that the slowdown poses a significant threat to business performance.
- Confidence in Future Investments: Despite facing short-term challenges, Mahoney reiterated the company's comfort with its guidance ranges for the second quarter and the full year, emphasizing ongoing investments across its businesses to support future growth.
See More
Boston Scientific Invests $1.5 Billion in MiRus for TAVR Market Entry
- Market Entry Strategy: Boston Scientific's $1.5 billion investment in MiRus LLC for a 34% stake positions the company in the transcatheter aortic valve replacement (TAVR) market, projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033, demonstrating its commitment to expansion in the medical device sector.
- Acquisition Potential: This investment not only grants Boston Scientific immediate ownership of one-third of MiRus but also lays the groundwork for a potential 100% acquisition, allowing for an additional $3 billion payment if MiRus's TAVR system meets specific milestones, thereby mitigating investment risks.
- Insider Buying Signal: While 92% of analysts rate Boston Scientific as a buy, the recent purchase of over $500,000 in shares by three directors indicates strong insider confidence in the company's future, further bolstering market sentiment towards the stock.
- Buyback Plan and Growth Outlook: Boston Scientific has also announced a $2 billion accelerated buyback program, signaling management's favorable view of the stock's valuation, while analysts project earnings growth of over 16% annually over the next three to five years, making the current stock price appear attractive.
See More
Boston Scientific Shares Plunge 12.64% Amid Soft Growth Outlook
- Weak Guidance: Boston Scientific's management reiterated its full-year organic growth guidance, projecting organic sales growth between 5.5% and 7% for 2026 and 6% to 8% for Q2, but analysts believe the lower end may be more realistic due to flat sales growth expectations for the WATCHMAN device.
- Severe Market Reaction: The company's stock closed at $50.42 on Wednesday, down 12.53% from the previous day, with trading volume reaching 49.5 million shares, about 191% above its three-month average, indicating market concerns over the company's outlook.
- Challenges for WATCHMAN: Although the WATCHMAN device remains the market share leader in its niche, its slowdown in growth has diminished investor confidence in future sales, particularly with muted expectations for Q2 and Q3.
- Industry Pressure: Peers like Abbott and Stryker also faced declines of 1.14% and 2.24%, respectively, reflecting broader pressures across the medical device sector, prompting investors to reassess the market environment.
See More
Boston Scientific Shares Drop 12.53% Amid Soft Growth Guidance
- Stock Price Decline: Boston Scientific (BSX) closed at $50.42 on Wednesday, down 12.53%, primarily due to management reiterating soft full-year organic growth guidance and signaling weaker demand in key WATCHMAN and urology franchises.
- Surge in Trading Volume: The company experienced a trading volume of 49.5 million shares, approximately 191% above its three-month average of 17 million shares, indicating strong market reactions to its outlook.
- Adjusted Growth Expectations: While the company projects organic sales growth of 5.5% to 7% for 2026, analysts believe the lower end of this guidance may be more realistic due to expectations of flat sequential sales growth for the WATCHMAN device in Q2 and Q3.
- Competitive Market Pressure: Competitors in the medical device sector, such as Abbott and Stryker, also faced declines, closing at $85.68 (-1.14%) and $305.99 (-2.24%), reflecting broader industry challenges.
See More
Boston Scientific Lowers Guidance Amid Market Challenges
- Guidance Revision: Boston Scientific has revised its 2026 net sales growth expectations down to 7% to 8.5%, a significant drop from the previous forecast of 10.5% to 11.5%, indicating pressures from a slowdown in the WATCHMAN business and market share erosion by competitors.
- WATCHMAN Business Challenges: CEO Mahoney highlighted stagnation in the WATCHMAN business, with expectations of flat dollar growth in Q2 and Q3, reflecting intensified competition in this segment.
- Urology Market Weakness: The company faces challenges in its urology business from niche competitors, and the Axonics overactive bladder segment has experienced commercial disruptions, although Boston Scientific has hired around 100 new clinical representatives to adapt to market changes.
- Ongoing R&D Investment: Boston Scientific continues to allocate over 9% of its revenue to internal R&D and maintains the largest venture fund in the medtech sector, demonstrating its commitment to future technological innovations.
See More
Prosight Management Increases Stake in Nektar Therapeutics
- Share Increase: On May 15, 2026, Prosight Management disclosed an increase of 180,367 shares in Nektar Therapeutics, valued at approximately $10.27 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The total value of Nektar's shares rose by $29.43 million at the end of the quarter, reflecting the dual impact of trading activity and share price appreciation, further solidifying Prosight's significance in its investment portfolio.
- Improved Financial Position: Nektar's revenue increased from $10.5 million to $10.9 million in the first quarter, with cash and marketable securities reaching $731.6 million, showcasing its relative strength among clinical-stage biotech peers.
- Clinical Development Outlook: Nektar's rezpegaldesleukin treatment has shown encouraging data in trials, with plans to initiate the Phase 3 ZENITH-AD program in July, which could significantly enhance the company's valuation if successful.
See More
Boston Scientific Shares Hit 52-Week Low Amid Demand Slowdown
- Demand Slowdown Impact: Boston Scientific (BSX) shares fell approximately 10% in the morning on Wednesday, reaching a 52-week low primarily due to a persistent slowdown in demand for its WATCHMAN cardiac implant, indicating a weakening market for this product.
- Lowered Growth Outlook: During its Q1 2026 earnings release, the company revised its full-year organic net sales growth forecast down to 6.5%-8.0%, largely attributed to headwinds in WATCHMAN volumes and its electrophysiology business in the U.S.
- Market Share Challenges: CEO Michael Mahoney confirmed at an investor conference that standalone WATCHMAN growth remains a challenge, despite the company holding a 90%-91% market share in that area, indicating that the slowdown poses a significant threat to business performance.
- Confidence in Future Investments: Despite facing short-term challenges, Mahoney reiterated the company's comfort with its guidance ranges for the second quarter and the full year, emphasizing ongoing investments across its businesses to support future growth.
See More
Boston Scientific Invests $1.5 Billion in MiRus for TAVR Market Entry
- Market Entry Strategy: Boston Scientific's $1.5 billion investment in MiRus LLC for a 34% stake positions the company in the transcatheter aortic valve replacement (TAVR) market, projected to grow from $4.5 billion in 2024 to $12.2 billion by 2033, demonstrating its commitment to expansion in the medical device sector.
- Acquisition Potential: This investment not only grants Boston Scientific immediate ownership of one-third of MiRus but also lays the groundwork for a potential 100% acquisition, allowing for an additional $3 billion payment if MiRus's TAVR system meets specific milestones, thereby mitigating investment risks.
- Insider Buying Signal: While 92% of analysts rate Boston Scientific as a buy, the recent purchase of over $500,000 in shares by three directors indicates strong insider confidence in the company's future, further bolstering market sentiment towards the stock.
- Buyback Plan and Growth Outlook: Boston Scientific has also announced a $2 billion accelerated buyback program, signaling management's favorable view of the stock's valuation, while analysts project earnings growth of over 16% annually over the next three to five years, making the current stock price appear attractive.
See More
Boston Scientific Shares Plunge 12.64% Amid Soft Growth Outlook
- Weak Guidance: Boston Scientific's management reiterated its full-year organic growth guidance, projecting organic sales growth between 5.5% and 7% for 2026 and 6% to 8% for Q2, but analysts believe the lower end may be more realistic due to flat sales growth expectations for the WATCHMAN device.
- Severe Market Reaction: The company's stock closed at $50.42 on Wednesday, down 12.53% from the previous day, with trading volume reaching 49.5 million shares, about 191% above its three-month average, indicating market concerns over the company's outlook.
- Challenges for WATCHMAN: Although the WATCHMAN device remains the market share leader in its niche, its slowdown in growth has diminished investor confidence in future sales, particularly with muted expectations for Q2 and Q3.
- Industry Pressure: Peers like Abbott and Stryker also faced declines of 1.14% and 2.24%, respectively, reflecting broader pressures across the medical device sector, prompting investors to reassess the market environment.
See More
Boston Scientific Shares Drop 12.53% Amid Soft Growth Guidance
- Stock Price Decline: Boston Scientific (BSX) closed at $50.42 on Wednesday, down 12.53%, primarily due to management reiterating soft full-year organic growth guidance and signaling weaker demand in key WATCHMAN and urology franchises.
- Surge in Trading Volume: The company experienced a trading volume of 49.5 million shares, approximately 191% above its three-month average of 17 million shares, indicating strong market reactions to its outlook.
- Adjusted Growth Expectations: While the company projects organic sales growth of 5.5% to 7% for 2026, analysts believe the lower end of this guidance may be more realistic due to expectations of flat sequential sales growth for the WATCHMAN device in Q2 and Q3.
- Competitive Market Pressure: Competitors in the medical device sector, such as Abbott and Stryker, also faced declines, closing at $85.68 (-1.14%) and $305.99 (-2.24%), reflecting broader industry challenges.
See More
Boston Scientific Lowers Guidance Amid Market Challenges
- Guidance Revision: Boston Scientific has revised its 2026 net sales growth expectations down to 7% to 8.5%, a significant drop from the previous forecast of 10.5% to 11.5%, indicating pressures from a slowdown in the WATCHMAN business and market share erosion by competitors.
- WATCHMAN Business Challenges: CEO Mahoney highlighted stagnation in the WATCHMAN business, with expectations of flat dollar growth in Q2 and Q3, reflecting intensified competition in this segment.
- Urology Market Weakness: The company faces challenges in its urology business from niche competitors, and the Axonics overactive bladder segment has experienced commercial disruptions, although Boston Scientific has hired around 100 new clinical representatives to adapt to market changes.
- Ongoing R&D Investment: Boston Scientific continues to allocate over 9% of its revenue to internal R&D and maintains the largest venture fund in the medtech sector, demonstrating its commitment to future technological innovations.
See More
Prosight Management Increases Stake in Nektar Therapeutics
- Share Increase: On May 15, 2026, Prosight Management disclosed an increase of 180,367 shares in Nektar Therapeutics, valued at approximately $10.27 million, indicating strong confidence in the company's future prospects.
- Market Value Growth: The total value of Nektar's shares rose by $29.43 million at the end of the quarter, reflecting the dual impact of trading activity and share price appreciation, further solidifying Prosight's significance in its investment portfolio.
- Improved Financial Position: Nektar's revenue increased from $10.5 million to $10.9 million in the first quarter, with cash and marketable securities reaching $731.6 million, showcasing its relative strength among clinical-stage biotech peers.
- Clinical Development Outlook: Nektar's rezpegaldesleukin treatment has shown encouraging data in trials, with plans to initiate the Phase 3 ZENITH-AD program in July, which could significantly enhance the company's valuation if successful.
See More
